| text only |
|
|||||||||||||||||||||||||||||
Professional Profile
Research Interests: -DNA damage and repair, as it relates to the clinical use of anticancer agents and to human carcinogens. Particular emphasis is given to the identification and manipulation of factors that modulate DNA damage levels and DNA repair efficiency. -The treatment of gynecologic and genitourinary malignancies. -New agent development. -The science of health care disparity. -The clinical, molecular, and public health aspects of cancer prevention. Honors and Academic Achievements: -Chairperson, Scientific Review Committee. American Association for Cancer Research, Gertrude B. Elion Cancer Research Award, Philadelphia, PA., 2009 -Chairperson, Scientific Review Panel. NCMHD Bioethics Research Centers-ARRA grants. Bethesda, Maryland, 2009 -American Association for Cancer Research Board of Director, 2008-11 -Institute of Medicine National Cancer Policy Forum, member, 2005-08 -C-Change, Washington, D.C., member, 2005-08 Education: -Fellowship, Medical Oncology, NCI, Bethesda, Maryland, 1985 -Internship and Residency, Stanford University, Palo Alto, California, 1981 -M.D., Yale University, New Haven, Connecticut, 1979 -B.S., Philander Smith College, Little Rock, Arkansas, 1975 Professional Appointments: -1985 – 1987 Special Assistant for Preclinical Science, Office of the Director (B. A. Chabner, Dir) Division of Cancer Treatment, NCI, Bethesda, Maryland -1987 – 2001 Senior Staff, USPHS (tenured scientist 1991-2001); Division of Clinical Sciences, NCI (Medicine Branch and Clinical Pharmacology Branch) -1993 – 1996 Chief, Clinical Pharmacology Branch, Division of Clinical Sciences (DCS), NCI -1993 – 2001 Chief, Ovarian Cancer and Metastatic Prostate Cancer Clinic, DCS, NCI -2001 – 2005 Director, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, W V -2005 – 2008 Director, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia -2008 –present Professor, Oncologic Sciences; and, Abraham Mitchell Distinguished Investigator; Mitchell Cancer Institute; University of South Alabama, Mobile, Alabama Professional Associations: -Alabama State Medical Association -American Association for Cancer Research -American Public Health Association -American Society of Clinical Oncology -American Society for Clinical Pharmacology and Therapeutics -Arkansas Medical, Dental, and Pharmaceutical Association -Association for Academic Minority Physicians -DeKalb County Medical Association, DeKalb County, GA -Environmental Mutagen Society -Gynecologic Oncology Group (GOG) -International Association of Environmental Mutagen Societies -International Gynecologic Cancer Society -Medical Association of Georgia -Medical Society of Mobile County -Mid-Atlantic Gynecologic Oncology Society -Molecular Epidemiology Group, AACR -Monongalia County Medical Association -National Medical Association -Society of Gynecologic Oncology (SGO) -West Virginia State Medical Association Scientific Focus: Nucleotide excision repair; and, the pharmacologic manipulation of DNA damage and repair by anticancer agents. Selected Publications:
Older Highly Cited Publications 1. Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V.A., Egwuagu, C., and Reed, E. (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84: 1512-1517 (cited more than 180 times). 2. Dabholkar, M., Vionnet, J., Bostickbruton, F., Yu, J.J., and Reed, E. (1994) Messenger-RNA levels of XPAC and ERCC1 in ovarian-cancer tissue correlate with response to platinum-based chemotherapy. J. Clin Invest 94: 703-708 (cited more than 225 times). 3. Kohn, E.C., Sarosy, G., Bicher, A., Link, C., Christian, M., Steinberg, S., Rothenberg, M., Adamo, D.O., Davis, P., Ognibene, F., Cunnion, R., and Reed, E. (1994) Taxol: High dose intensity increases the objective response rate in platinum-resistant ovarian cancer patients. J Natl Cancer Inst 86: 18-24 (cited more than 164 times). 4. Reed E. (1998) Platinum-DNA adduct, nucleotide excision repair, and platinum based anti-cancer chemotherapy. Cancer Treatment Reviews 24: 331-344 (cited more than 148 times). Recent Publications 1. Reed, E. (2008) Cisplatin, and platinum analogs. In: Cancer Principles and Practice of Oncology; 8th Edition (V T DeVita, S A Rosenberg, T S Lawrence, eds), Lippincott, Williams, and Wilkins; Philadelphia, pp.419-426. 2. Gao, R., Price, D.K., Sissung, T., Reed, E., and Figg, W.D. (2008) Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. Mol Cancer Ther. 7(5): 1246-1250. 3. Seeff, L.C, DeGroff, A., Tangka, F., Wanliss, E., Major, A., Nadel, M., Ryerson, A. B., Royalty, J., Gelb, C., and Reed, E. (2008) The development of a Federally-funded demonstration colorectal cancer screening program. Preventing Chronic Disease [serial online]: Apr;5(2): A64. 4. Wang, Y., Wiltshire, T., Senft, J., Reed, E., and Wang, W. (2007) Irofulven induces replication-dependent CHK2 activation related to p53 status. Biochemical Pharmacology 73: 469-480. 5. Darcy, K.M., Tian, C., and Reed, E. (2007) Platinum-DNA adducts and ERCC1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy: a Gynecologic Oncology Group study. Cancer Res 67: 4474-4481. 6. Reed, E. (2006) ERCCI measurements in clinical oncology. New Eng J. Med 355: 1054-1055. |
||||
Eddie Reed, M.D.University of South Alabama - Mobile Alabama 36688-0002 Appointments: Medical, Surgical and Gynecologic Oncology: (251) 665-8000 Radiation Oncology: (251) 445-9615 Administration: (251) 460-6993 For questions or comments Contact Us Date last changed: October 15, 2009 9:39 AM http://www.southalabama.edu/mci/reed2.html |
 |